There is a reason for HZNP to be at this level.
Investors are waiting for any bad news and they probably know that some bad news are hidden and can be released at any time.
Are you kidding me? TW wanted DEPO so bad that he was going to do everything possible to get it. Here is a company with better products, more revenue and almost no debt and at least $1 cheaper with 3 products in phase III and a few more in other phases. In addition it is company with international reach.
If HZNP goes after ACOR, then HZNP price will jump over $20 right away.
Offer ACOR $2B with all HZNP shares. It will be around 130m shares.
ACOR will add more revenue to HZNP than DEPO but also, ACOR has cash and very small debt (positive cash - debt). But ACOR has 3 products in phase III which will put HZNP in category of big pharmas with huge development.
I think DEPO will do well. Now, the market cap is so low that is trading below Nucynta price.
Lets shave off $100m early next month while accumulate more cash. Time is in favor of DEPO without price gouging and other problems that the sector is facing.
ACOR is another stock that I am holding with 3 drugs in phase III and positive income and cash minus debt.
HZNP is facing several lawsuit and it may lose money in this process.
DEPO is suing Purdue for millions, it may be hundreds of million.
So, between HZNP and DEPO, which is better?
I am holding ACOR, SCMP, HZNP and DEPO.
Why are you wasting your time here.
That 14.9% is less than 2k of ACOR.
NeurogesX is one single penny per share and soon becomes zero per share.
M&A is good for sector.
DEPO can claim millions for damages. I think $200m to $500m is possible unless Purdue buys DEPO at $40 per share.